1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Anti-Obesity Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 Peripherally Acting Drugs
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Centrally Acting Drugs
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug Type
7.1 Prescription Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 OTC Drugs
7.2.1 Market Trends
7.2.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Retail Pharmacy
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Pharmacy
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Boehringer Ingelheim International GmbH
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.2 Currax Pharmaceuticals LLC
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.3 Gelesis
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 GlaxoSmithKline plc
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 Merck & Co. Inc.
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.5.4 SWOT Analysis
14.3.6 Norgine B.V.
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.7 Novo Nordisk A/S
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.9 Rhythm Pharmaceuticals Inc.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.10 SHIONOGI & Co. Ltd.
14.3.10.1 Company Overview
14.3.10.2 Product Portfolio
14.3.10.3 Financials
14.3.10.4 SWOT Analysis
14.3.11 Takeda Pharmaceutical Company Limited
14.3.11.1 Company Overview
14.3.11.2 Product Portfolio
14.3.11.3 Financials
14.3.11.4 SWOT Analysis
14.3.12 Vivus LLC
14.3.12.1 Company Overview
14.3.12.2 Product Portfolio
世界の抗肥満薬市場予測2022年-2027年 |
| 【英語タイトル】Anti-Obesity Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027 | |
 | ・商品コード：IMARC22OT0055 ・発行会社（調査会社）：IMARC ・発行日：2022年6月13日 ・ページ数：143 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール ・調査対象地域：グローバル ・産業分野：医薬品 |
| Single User | USD2,499 ⇒換算￥324,870 | 見積依頼/購入/質問フォーム |
| Five User | USD3,499 ⇒換算￥454,870 | 見積依頼/購入/質問フォーム |
| Enterprisewide | USD4,499 ⇒換算￥584,870 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| IMARC社では、世界の抗肥満薬市場規模が2021年17.8億ドルから2027年36.3億ドルに達し、2022年から2027年まで年平均12.20％成長すると予測しています。本調査レポートでは、抗肥満薬の世界市場を調査・分析し、序論、範囲・調査手法、エグゼクティブサマリー、イントロダクション、薬物クラス別（末梢性作用薬、中枢性薬）分析、薬種類別（処方薬、OTC医薬品）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、アジア太平洋、ヨーロッパ、中東・アフリカ、中南米）分析、SWOT分析、バリューチェーン分析、ファイブフォース分析、価格分析、競争状況などの項目を掲載しています。なお、当書に掲載されている企業情報には、Boehringer Ingelheim International GmbH、Currax Pharmaceuticals LLC、Gelesis、GlaxoSmithKline plc、Merck & Co. Inc.、Norgine B.V.、Novo Nordisk A/S、Pfizer Inc.、Rhythm Pharmaceuticals Inc.、SHIONOGI & Co. Ltd.、Takeda Pharmaceutical Company Limited、 Vivus LLC.などが含まれています。 ・序論 ・範囲・調査手法 ・エグゼクティブサマリー ・イントロダクション ・世界の抗肥満薬市場規模：薬物クラス別 - 末梢性作用抗肥満薬の市場規模 - 中枢性抗肥満薬の市場規模 ・世界の抗肥満薬市場規模：薬種類別 - 処方用抗肥満薬の市場規模 - OTC医薬品用抗肥満薬の市場規模 ・世界の抗肥満薬市場規模：流通チャネル別 - 病院薬局流通チャネルの市場規模 - 小売薬局流通チャネルの市場規模 - オンライン薬局流通チャネルの市場規模 ・世界の抗肥満薬市場規模：地域別 - 北米の抗肥満薬市場規模 - アジア太平洋の抗肥満薬市場規模 - ヨーロッパの抗肥満薬市場規模 - 中南米の抗肥満薬市場規模 - 中東・アフリカの抗肥満薬市場規模 ・SWOT分析 ・バリューチェーン分析 ・ファイブフォース分析 ・価格分析 ・競争状況 |
The global anti-obesity drugs market reached a value of US$ 1.78 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.63 Billion by 2027, exhibiting a CAGR of 12.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Anti-obesity drugs are intended to reduce or control weight and generally medically prescribed only in cases of morbid obesity. They help reduce cravings and control compulsive eating, especially for sweets and fatty, salty, and high-calorie food products. They can also provide independent health benefits, such as controlling blood pressure, harmful lipid levels, waist circumference, sugar levels and nonalcoholic fatty liver disease (NAFLD) and minimize the risk of major cardiovascular diseases (CVDs) and progression of diabetic kidney disease.
Anti-Obesity Drugs Market Trends:
Recent advances in anti-obesity drugs have enabled the potential of attaining clinically significant weight loss among individuals. This, in confluence with the widespread prevalence of obesity on account of sedentary lifestyles, represents one of the key factors creating a positive outlook for the market. In addition, obesity increases the risk of developing type 2 diabetes (T2D), cardiovascular diseases (CVD), and cancer of the esophagus, colon and rectum, liver, gallbladder, pancreas, and kidney. It can also result in numerous psychological, neurological, pulmonary, gastrointestinal, renal, musculoskeletal, and endocrine diseases. Besides this, sleep deprivation, circadian desynchronization, chronic stress, and the rising use of anti-epileptic and psychotropic drugs may further induce weight gain. This, coupled with the increasing number of approvals of anti-obesity medications (AOMs) that help regulate appetite and food cravings, is fueling the growth of the market. Apart from this, weight loss aids in improving the quality of life, mobility, daily function, and psychological well-being of individuals. This, along with the increasing health consciousness, thriving pharmaceutical industry, and the rising focus on the management of diseases closely integrated with excess body weight, is anticipated to stimulate the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global anti-obesity drugs market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, drug type and distribution channel.
Breakup by Drug Class:
Peripherally Acting Drugs
Centrally Acting Drugs
Breakup by Drug Type:
Prescription Drugs
OTC Drugs
Breakup by Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Boehringer Ingelheim International GmbH, Currax Pharmaceuticals LLC, Gelesis, GlaxoSmithKline plc, Merck & Co. Inc., Norgine B.V., Novo Nordisk A/S, Pfizer Inc., Rhythm Pharmaceuticals Inc., SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Vivus LLC.
Key Questions Answered in This Report:
How has the global anti-obesity drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global anti-obesity drugs market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global anti-obesity drugs market and who are the key players?
What is the degree of competition in the industry?
| ★調査レポート[世界の抗肥満薬市場予測2022年-2027年] (コード：IMARC22OT0055)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の抗肥満薬市場予測2022年-2027年]についてメールでお問い合わせ |
